in this issue
Pharma/fine chemicals roundup—18 December
8:10 AM MST | December 18, 2012 | By DEEPTI RAMESH
Ampac Fine Chemicals reports operating profits
Ampac Fine Chemicals (AFC; Rancho Cordova, CA), a subsidiary of American Pacific Corp. (Las Vegas), recorded an operating profit of about $3.9 million in its fiscal fourth quarter, ended 30 September 2012, compared with an operating loss of $1.4 million in the corresponding period of the previous fiscal year. Fourth-quarter sales increased 15%, to $33.1 million. In the full fiscal year ended 30 September, AFC recorded a 25% increase in sales compared with the previous fiscal year, to $111.5 million, and an operating profit of $7 million compared with an operating loss of $9.2 million in the previous fiscal year.
Tessenderlo completes sale of pharmaceutical ingredients business
Tessenderlo Group (Brussels) says it has completed the previously announced sale of its pharmaceutical ingredients subsidiaries Calaire Chimie (Calais, France) and Farchemia (Treviglio, Italy) to the International Chemical Investors Group, a private industrial holding company. Plans for the sale were announced last October. Information and consultation procedures were completed in early November and, following clearance by the merger control authorities, the sale was completed on 5 December, Tessenderlo says.
Elite Pharmaceuticals signs API supply deal
Elite Pharmaceuticals (Northvale, NJ) says it has in place an agreement for the next year with the company’s sole supplier of the active pharmaceutical ingredient (API) for Elite’s phentermine product lines. A supply limitation was disclosed by Elite last October but is now resolved for the next year. The purchase orders now in place will allow the company to obtain adequate amounts of the API, although at a substantially higher price than previously paid, to supply both the phentermine tablet product and the soon-to-be-launched phentermine capsule products, Elite says. Elite anticipates that some of the increase in API pricing could be offset with increased manufacturing efficiencies.
Aesica partners with Durham and Leeds universities to commercialize API manufacturing technology
Aesica Pharmaceuticals (Newcastle upon Tyne, UK), the University of Durham (Durham, UK), and the University of Leeds (Leeds, UK) were jointly awarded the METRC innovation grant to investigate and accelerate the development of processes that will improve cost efficiencies and increase manufacturing capacity at Aesica’s Cramlington, UK, site. The new partnership with the University of Durham and the University of Leeds will aim to develop new or improved routes for the manufacture of an active pharmaceutical ingredient (API), Aesica says.
BASF increases prices for ethanolamines in Europe
BASF says it is increasing its European sales prices for ethanolamines with immediate effect or as existing contracts permit. The prices for monoethanolamine, diethanolamine, and triethanolamine will increase by €80 ($105)/m.t. Ethanolamines are intermediates used in the manufacture of active pharmaceutical ingredients (APIs), agchems and wood protectants, surfactants for detergents and cleaning products, process chemicals for gas treatment, lubricants, and cement additives. BASF produces ethanolamines at Ludwigshafen; Antwerp; and Nanjing, China. The price increase will also apply to current supply agreements as soon as possible, and to the extent permitted by their terms and conditions, BASF says.